Chemours (CC)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
$13.79+5.35%
Close 2026-11-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
Research Workspace
Put CC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve free cash flow of at least $100 million in 2026: Comparison needs review.
View ThesisRevenue is contracting — down about 1% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 55% in its worst 12-month stretch.
View RiskChemours must hit its 2026 free cash flow target to justify the price. Revenue grew 3% year over year in the latest quarter. The company missed its earnings estimate by 19.2%. It trades at 19 times earnings versus a 16 times peer median. The price reflects less growth than our forecast. Our model puts the next-quarter miss probability near 53%. The thesis comparison is not yet verified. Peer multiples imply a price about 35% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. CC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 10 analysts currently covering CC (as of Nov 2026).
Based on 8 Wall Street analysts offering 12-month price targets for CC in the last 4 months.
Continue this research
Compare CC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Diversified Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put CC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Achieve Free Cash Flow of at least $50 million in 2026
EBITDA guidance supports FCF target achievement.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $13.79
The last 12 months of price, then the range of analyst 12-month targets from today’s $13.79.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Deliver 2026 Net Sales growth of 3% to 5% over 2025
Downgrade indicates potential sales growth issues.
Threatens: Deliver 2026 Net Sales growth of 3% to 5% over 2025
Downgrade indicates ongoing challenges in TiO2 market affecting growth.
Threatens: Deliver 2026 Net Sales growth of 3% to 5% over 2025
Weak chemical demand impacts growth outlook.
Threatens: Deliver 2026 Net Sales growth of 3% to 5% over 2025
Downgrade indicates potential sales growth challenges.
Threatens: Deliver 2026 Net Sales growth of 3% to 5% over 2025
Core demand slipping impacts growth objectives.
Lawsuit could impact financial stability and reputation.
Regulatory changes could impact sales and operations.